A renaissance in diabetic foot care: new evidence-based treatments
Edmonds M
Lancet Diabetes Endocrinol. September 19, 2018
Leggi
Breaking news
Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis
McGurnaghan S, Blackbourn LAK, Mocevic E, et al.
Diabet Med. Pub. online September 23, 2018
Leggi
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients with Type 2 Diabetes
Chang H-Y
JAMA Intern Med 2018;178(9):1190-8
Leggi
Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis
Udler MS, Kim J, von Grotthuss M, et al.
PLoS Med. Pub. online September 21, 2018
Leggi
Real-World Diabetes Prevention: From Theory to Practice
Ryder REJ
The Lancet Diabetes & Endocrinology. Pub. online 14 September 2018.
Leggi
Successful Treatment of Prediabetes in Clinical Practice Using Physiological Assessment (Stop Diabetes)
Armato JP, DeFronzo RA, Abdul-Ghani M, Ru RJ
The Lancet Diabetes & Endocrinology. Pub. online 14 September 2018.
Leggi
Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity
Lowe WL Jr, Scholtens DM, Lowe LP, et al.
JAMA. 2018; 320(10):1005-16.
Leggi
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula EA, Phil D, Wiviott SD, et al.
N Engl J Med. 2018;379(12):1107-17.
Leggi
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma S, McMurray JJV
Diabetologia 2018;61(10):2108-17
Leggi
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
Sattar N, Fitchett D, Hantel S, et al.
Diabetologia 2018;61(10):2155-63
Leggi